DVAX -Bullish RSI Divergence May Signal an Impending Move Higher

32 0 0
Eddie Gray ( CEO             ) & the rest of Dynavax's "A-Team" are unequivocally committed and, IMO             , well in the process of expanding/creating a diversified PL within a first class biotech franchise. I'm a firm believer that management's rigorous approach to drug development in the field of TLR biology and immune system modulation to attack the challenges of infectious and inflammatory diseases and cancer will extract maximum shareholder value over time; hence, also believe that shares are grossly undervalued at current levels. My LT             PT is actually $62.79 (not shown on this chart) but have provided several reference points (R-1 - R-5) that I think, eventually, will be achieved. Disclosure: Long via common equity. For reference only & not investment advice.
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out